Lantern Pharma Stock Today
| LTRN Stock | USD 3.13 0.05 1.62% |
Performance0 of 100
| Odds Of DistressLess than 19
|
Lantern Pharma is selling at 3.13 as of the 26th of November 2024; that is 1.62 percent increase since the beginning of the trading day. The stock's open price was 3.08. Lantern Pharma has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Lantern Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of January 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of June 2020 | Category Healthcare | Classification Health Care |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. The company has 10.78 M outstanding shares of which 165.56 K shares are now shorted by private and institutional investors with about 4.74 trading days to cover. More on Lantern Pharma
Moving together with Lantern Stock
Moving against Lantern Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lantern Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Panna Sharma | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsLantern Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lantern Pharma's financial leverage. It provides some insight into what part of Lantern Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Lantern Pharma (LTRN) is traded on NASDAQ Exchange in USA. It is located in 1920 McKinney Avenue, Dallas, TX, United States, 75201 and employs 21 people. Lantern Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.76 M. Lantern Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.78 M outstanding shares of which 165.56 K shares are now shorted by private and institutional investors with about 4.74 trading days to cover.
Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lantern Pharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Lantern Pharma is $33.76 Million. Lantern Pharma secures 14.74 % of its outstanding shares held by insiders and 24.1 % owned by institutional investors. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Lantern Ownership Details
Lantern Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Perigon Wealth Management, Llc | 2024-09-30 | 28.9 K | |
| Sigma Planning Corp | 2024-09-30 | 28.6 K | |
| Horizon Asset Management Inc/ny | 2024-09-30 | 27.6 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 26.5 K | |
| Ubs Group Ag | 2024-06-30 | 25.5 K | |
| State Street Corp | 2024-06-30 | 23.7 K | |
| Tocqueville Asset Management L.p. | 2024-09-30 | 17 K | |
| Meridian Wealth Management, Llc | 2024-06-30 | 14.9 K | |
| Northern Trust Corp | 2024-09-30 | 12.8 K | |
| Vanguard Group Inc | 2024-09-30 | 363.7 K | |
| Cm Management, Llc | 2024-09-30 | 185 K |
Lantern Pharma Historical Income Statement
Lantern Stock Against Markets
Lantern Pharma Corporate Management
| DVM MS | CoFounder Advisor | Profile | |
| Nicole Leber | Finance Associate | Profile | |
| MS BS | Head Operations | Profile | |
| Kishor Bhatia | Chief Consultant | Profile | |
| Marc MD | Chief Therapeutics | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.